Jasper Therapeutics, Inc. JSPR 深 沪
等待开盘 06-25 09:30:00 美东时间
0.4906
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.4906
- 总市值 1374.16万
- 52周最高 4.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.42
- 委 比 0.00%
- 总股本 2800.98万
- 历史最高 188.80
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.42
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Jasper Therapeutics Received Notice Of Non-Compliance With Nasdaq Minimum Bid Requirements On June 3
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001788028/000121390026066782/ea0294010-8k_jasper.htm
06-10 04:10
Jasper Therapeutics shares are trading lower. The company announced its Board has decided to initiate a comprehensive review of strategic alternatives to maximize shareholder value.
Jasper Therapeutics shares are trading lower. The company announced its Board h...
06-02 03:50
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
TD Cowen Downgrades Jasper Therapeutics to Hold
TD Cowen analyst Yaron Werber downgrades Jasper Therapeutics (NASDAQ:JSPR) from Buy to Hold.
05-16 00:45
RBC Capital Maintains Sector Perform on Jasper Therapeutics, Lowers Price Target to $3
RBC Capital analyst Leonid Timashev maintains Jasper Therapeutics (NASDAQ:JSPR) with a Sector Perform and lowers the price target from $4 to $3.
05-15 22:05
美股大行评级 | 绩后爆锤！耐克遭10家大行集体下调目标价；NCNO、RH、艾默生电气等也遭大行下调目标价
今日重点评级关注：Canaccord Genuity：维持Generac控股"买入"评级，目标价从275美元升至300美元；Oppenheimer：维持Biogen"跑赢大市"评级，目标价从250美元升至275美元
04-02 16:17
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7
Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and lowers the price target from $12 to $7.
04-02 01:06
Jasper Therapeutics Q4 EPS $(0.32) Beats $(0.64) Estimate
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.64) by 50.31 percent. This is a 80.25 percent increase over losses of $(1.62) per share
03-31 04:53
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock rose 19.6% to $1.4 during Frid...
02-13 20:05
Jasper Therapeutics Reports Updated Clinical Data From BEACON Phase 1b/2a Study Of Subcutaneous Briquilimab In Adult Participants With CSU, As Well As From Open Label Extension Study In CSU And CIndU
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points 75% of CSU participants (n=36) enrolled in the open label extension
01-08 20:09
